EUVIMEDEUVIMED entdecken
Crossref

Discovery of digallic acid as XOD/URAT1 dual target inhibitor for the treatment of hyperuricemia

Fengxin Zheng, Suiqing Mai, Xiaolin Cen, Pei Zhao, Wenjie Ye, Jiale Ke, Shiqin Lin, Huazhong Hu, Zitao Guo, Shuqin Zhang, Hui Liao, Ting Wu und 4 weitere

Bioorganic Chemistry · 2024-06 · 147 · 107381

DOI: 10.1016/j.bioorg.2024.107381 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024-06. Verfasst von Fengxin Zheng und 15 weiteren Autor:innen. Beteiligte Einrichtung: NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-M…. Hauptthemen laut MEDLINE: Hyperuricemia, Organic Anion Transporters, Organic Cation Transport Proteins, Enzyme Inhibitors. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of XOD/URAT1 dual target inhibitors has emerged as a promising therapeutic strategy for the management of hyperuricemia. Here, through virtual screening, we have identified digallic acid as a novel dual target inhibitor of XOD/URAT1 and subsequently evaluated its pharmacological properties, pharmacokinetics, and toxicities. Digallic acid inhibited URAT1 with an IC50 of 5.34 ± 0.65 μM, which is less potent than benzbromarone (2.01 ± 0.36 μM) but more potent than lesinurad (10.36 ± 1.23 μM). Docking and mutation analysis indicated that residues S35, F241 and R477 of URAT1 confer a high affinity for digallic acid. Digallic acid inhibited XOD with an IC50 of 1.04 ± 0.23 μM. Its metabolic product, gallic acid, inhibited XOD with an IC50 of 0.91 ± 0.14 μM. Enzyme kinetic studies indicated that both digallic acid and gallic acid act as mixed-type XOD inhibitors. It shares the same binding mode as digallic acid, and residues E802, R880, F914, T1010, N768 and F1009 contribute to their high affinity. The anion group (carboxyl) of digallic acid contribute significantly to its inhibition activity on both XOD and URAT1 as indicated by docking analysis. Remarkably, at a dosage of 10 mg/kg in vivo, digallic acid exhibited a stronger urate-lowering and uricosuric effect compared to the positive drug benzbromarone and lesinurad. Pharmacokinetic study indicated that digallic acid can be hydrolyzed into gallic acid in vivo and has a t1/2 of 0.77 ± 0.10 h. Further toxicity evaluation indicated that digallic acid exhibited no obvious renal toxicity, as reflected by CCK-8, biochemical analysis (CR and BUN) and HE examination. The findings of our study can provide valuable insights for the development of XOD/URAT1 dual target inhibitors, and digallic acid deserves further investigation as a potential anti-hyperuricemic drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperuricemiaOrganic Anion TransportersOrganic Cation Transport ProteinsEnzyme InhibitorsDose-Response Relationship, DrugHumansAnimalsStructure-Activity RelationshipMolecular StructureUrate OxidaseDrug DiscoveryMolecular Docking SimulationMiceMaleGallic AcidRats, Sprague-Dawley

Stichwörter der Autor:innen

GoutHyperuricemiaUrate transporter 1Xanthine oxidase

Substanzen

Organic Anion TransportersOrganic Cation Transport ProteinsEnzyme InhibitorsUrate OxidaseGallic AcidSLC22A12 protein, human

Autor:innen und Institutionen

  • NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical…
  • Good Clinical Practice Development, Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China.
  • Good Clinical Practice Development, Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China. Electronic address: zhangqun…
  • Good Clinical Practice Development, Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China; NMPA Key Laboratory for Rese…
  • Good Clinical Practice Development, Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China. Electronic address: zhaozean…

Zitieren

APA

Zheng, F., Mai, S., Cen, X., Zhao, P., Ye, W., Ke, J., Lin, S., Hu, H., Guo, Z., Zhang, S., Liao, H., Wu, T., Tian, Y., Zhang, Q., Pang, J., & Zhao, Z. (2024). Discovery of digallic acid as XOD/URAT1 dual target inhibitor for the treatment of hyperuricemia. Bioorganic Chemistry, 147, 107381. https://doi.org/10.1016/j.bioorg.2024.107381

Vancouver

Zheng F, Mai S, Cen X, Zhao P, Ye W, Ke J, et al. Discovery of digallic acid as XOD/URAT1 dual target inhibitor for the treatment of hyperuricemia. Bioorganic Chemistry. 2024;147:107381. doi:10.1016/j.bioorg.2024.107381

BibTeX
@article{Zheng2024,
  author = {Zheng, Fengxin and Mai, Suiqing and Cen, Xiaolin and Zhao, Pei and Ye, Wenjie and Ke, Jiale and Lin, Shiqin and Hu, Huazhong and Guo, Zitao and Zhang, Shuqin and Liao, Hui and Wu, Ting and Tian, Yuanxin and Zhang, Qun and Pang, Jianxin and Zhao, Zean},
  title = {Discovery of digallic acid as XOD/URAT1 dual target inhibitor for the treatment of hyperuricemia},
  journal = {Bioorganic Chemistry},
  year = {2024},
  volume = {147},
  pages = {107381},
  doi = {10.1016/j.bioorg.2024.107381}
}
Kostenlos starten →